Arbutus Biopharma Corp
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-76.9% vs price
Base Case (Median)
-43.7% vs price
Bull Case (75th pct.)
112.3% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $-0.47 | -109.9% | High (40%) |
| PE Comparable | $17.36 | 268.5% | Medium (25%) |
| Graham Number | $2.65 | -43.8% | Medium (40%) |
Based on 3 out of 8 methods, ABUS appears fairly valued at the current price of $4.71. The base case fair value of $2.65 implies 43.7% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.